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Background In an autopsy senes, 10
out of 27 deaths in which 'idiopathic'
pulmonary emboli were discerned äs the
sole cause of death had occurred in
psychiatnc patients
Aims To investigate whether
antipsychotic medication is a nsk factor for
venous thrombosis
Method A descnption of the 10
psychiatnc patients was obtamed from the
pulmonary emboli autopsy reports We
carned out a bnef historic overview of the
literature We re-analysed data from the
LeidenThrombophilia Study (LETS), a
case-control study on patients with
venous thrombosis
Results In the autopsy reports, five out
of 10 psychiatnc patients with fatal
pulmonary embolism had confirmed use
of antipsychotic drugs After the
apphcation of chlorpromazme and its
analogues a higher mcidence of venous
thrombosis in psychiatnc patients was
descnbed in the German literature
between 1953 and 1977 In the re-analysis
ofthe LETS case-control study, four
patients used antipsychotic drugs versus
none inthecontrol group Recent
epidemiological studies of good
methodological quality have confirmed
thesefindmgs
Conclusions Venous thrombosis
appears to be associated with the use of
antipsychotic drugs in psychiatnc patients
Declaration of Enterest None
In a study to investigate a genetic basis for
fatal pulmonary embolism m autopsy re-
cords at the Leiden Umversity Medical
Center, 10 out of 27 deaths in which pul-
monary emboli were discerned äs the sole
cause of death and in which no other major
underlymg nsk factor was present had
occurred in psychiatnc or psychogeriatnc
patients (Vandenbroucke et al, 1998).
Inspired by this unanticipated findmg, we
searched the literature for studies on throm-
bosis m psychiatnc patients. A number of
papers, mostly in German literature between
1966 and 1984, reported an association
between psychiatnc illness and thrombosis,
m particular pulmonary embolism. In 1997
this association received renewed attention
m a study about mortality in people takmg
clozapme (Walker et al, 1997). In 2000,
new studies reported a sigmficantly m-
creased nsk of venous thrombosis m pa-
tients exposed to antipsychotic drugs
(Hagg et al, 2000; Thomassen et al, 2000;
Zornberg & Jick, 2000).
We present a comprehensive report of
the 10 psychiatnc patients from the Leiden
autopsy reports, and give a bnef histonc
overview of the literature dealmg with ve-
nous thrombosis in psychiatry. We also pre-
sent secondary analyses of a case-control
study on nsk factors for venous thrombo-
sis, the Leiden Thrombophilia Study (LETS;
Koster et al, 1993).
METHODS
Autopsy records
At the Leiden Umversity Medical Center,
14 000 autopsy records from 1970 until
mid-1994 were reviewed to select those in
which pulmonary embolism was the sole
cause of death. Only 27 autopsies fulfilled
this cntenon. Ten of these autopsies had
occurred in psychiatnc patients (Vanden-
broucke et al, 1998). In order to find a
common charactenstic other than the psy-
chiatnc illness, we reviewed the original
autopsy reports of the 10 psychiatnc pa-
tients in detail. The autopsy reports m-
cluded additional Information such äs a
bnef history of the admission or a copy of
the discharge letter. We looked at age, gen-
der, psychiatnc diagnosis, hospital admis-
sion time, medication use, and clues for
immobilisation and somatic illness prior
to the pulmonary embolism.
Historic literature overview
Based on our fmdings in the autopsy record
study we searched Medlme from 1960 to
1998 for matenal on the subject of psy-
chiatry and venous thrombosis, specifically
antipsychotic medication and pulmonary
embolism.
Case-control study
Details about the methodology of the case-
control study have been pubhshed earlier
(Koster et al, 1993). In bnef, from 1990
to 1993, 474 mcident cases with a first epi-
sode of deep-vem thrombosis, in whom
objective tests had confirmed the diagnoses,
were selected from three anticoagulation
clinics. In the Netherlands, anticoagulation
chmcs monitor coumann treatment for
virtually all patients diagnosed with venous
thrombosis m well-defmed geographic
areas. The study was hmited to out-
patients. Psychiatrie m-patients or general
hospital m-patients who were m the hospi-
tal at the time of enrolment were excluded.
The patients were asked to find a control
subject of the same gender, about the same
age, who was not a biological relative, had
no history of thrombosis or mahgnant
disorders and did not use coumanns. This
population-based case-control study was
used to estimate the nsk of a first episode
of deep-vem thrombosis m relation to sev-
eral clottmg factor abnormahties (Koster
et al, 1993).
Participants were asked to report any
medication use. Comorbidity and medical
treatments were assessed. Risk factors for
thrombosis such äs oral contraceptive use,
surgery, immobilisation and family history
were evaluated extensively. For patients
with a first episode of deep-vem thrombo-
sis, medical reports on the admission and
treatment were retneved. Patients older
than 70 years of age and patients with ma-
hgnancies were excluded. Fifty-one patients
declmed participation and 19 patients were
excluded because of psychiatnc morbidity
which would mterfere with participation
m the study (Koster et al, 1993).
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In the current re-analysis we investi-
gated the frequency of daily use from the
available records. First, we mvestigated the
patient and control groups for any daily
use of antipsychotics, antidepressants and
benzodiazepmes (mcludmg the mdex year
in which the first episode of deep-vem throm-
bosis occurred). Second, patients who re-
port usage of these drugs m the same year
äs the mdex date of their first thrombosis
were excluded to be certam that the medi-
cation was used prior to the first thrombo-
sis. Third, we restncted the analyses to
those patients with mono-therapeutic medi-
cation use, to rule out any mterference with
comedication and comorbid conditions.
Whether patients with a first episode of
deep-vem thrombosis used more medi-
cation in general, compared with the con-
trols, was checked for other commonly
used medications such äs beta-blockers and
antacids. Odds ratlos and 95% confidence
intervals were generated through Epi Info
6 (Centers for Disease Control and Preven-
tion & World Health Organization, 1997).
RESULTS
Autopsy records
Among the 10 psychiatnc patients there
was a considerable diversity in psychiatnc
diagnosis and penods of admission. None
of the patients had an acute psychotic epi-
sode pnor to the pulmonary embohsm. Five
patients had used antipsychotic drugs.
From the Information we could extract from
the autopsy reports this was the only com-
mon charactenstic. Table l shows gender,
age (mean and ränge) and presence of risk
Table l Antipsychotic medication, gender, mean
age and risk factors for thrombosis of psychiatnc

























factors in companson with the patients who
did not use antipsychotic drugs (n—2) or for
whom medication use was not reported
(«=3). The five patients who had taken
antipsychotic medication were younger
than those who had not, and no risk factors
for pulmonary embohsm were present in
any of them. Among the non-antipsychotic
users, three patients had impaired mobihty.
We concluded that the younger age at first
occurrence äs well äs the lack of immobili-
sation pomted to an association of anti-
psychotic drug use and venous thrombosis.
Historical literature overview
The discovery of the antipsychotic qualities
of chlorpromazine in 1953 was soon fol-
lowed by several case reports in the German
literature of fatal pulmonary embohsm
related to its use (Brehmer &c Ruckdeschel,
1953; Labhardt, 1954). A first case senes,
for the penod 1954-1957, reported on 11
(3.3%) cases of venous thrombosis and
pulmonary embohsm in a group of 338
phenothiazine users, compared with one
m a non-phenothiazme control group
(Grahmann & Suchenwirth, 1959). In
1963, Mahmodian (1963) observed a
three-fold increased risk of thrombosis m
the period 1958-1961 m psychiatnc and
neurological patients compared with the
years 1915-1922 (from 6% to 18% m males
and 10% to 29% m females). In 1966, Lal et
al (1966) reported on consecutive autopsies
on 357 psychiatnc patients diagnosed mamly
with schizophrema and a chronic bram
syndrome over the period 1961-1964.
The prevalence of pulmonary embohsm
found in those autopsies was 10%, which
was the same äs m all autopsies in the
general hospital population (Lal et al,
1966). However, the occurrence of pul-
monary embohsm m the general hospital
population is known to be high; so, the com-
parabihty with a general hospital population
m fact pomts to a high incidence. In a similar
study of 343 autopsy reports of psychiatnc
patients, Kendel & Fodor (1969) found
98 (29%) cases of pulmonary embohsm,
which m 16% was associated with acute
psychiatnc Symptoms. Scholz (1967) studied
37 psychiatnc patients with a pulmonary
embohsm äs the clmical cause of death.
Twenty-two patients had used antipsychotic
drugs. They were younger and in one-third
of the cases there was no explanatory comor-
bidity. Ziegler (1977) studied 688 autopsy
reports with pulmonary embohsm äs the sole
cause of death. Twenty-seven (4%) had an
underlymg psychiatnc disorder. Twelve
suffered from schizophrenia and 15 had a
depressive illness.
In a large observational study, Meier-
Ewert et al (1967) compared two groups
between 1953 and 1963. 1092 patients
with schizophrema or depression takmg
chlorpromazine, amitnptyhne or imipra-
mme and a group of 1172 similar
psychiatnc patients who did not use anti-
psychotic or antidepressant medication.
The frequency of thrombo-embohc comph-
cations m the medication group was 2.9%
versus 0.59% m the control group. How-
ever, 22 of the 34 medication users with a
thrombo-embohc comphcation showed
medical comorbidity. An interestmg obser-
vation was made in 1984: five women with
schizophrema, 33-58 years of age, suffered
from deep-venous thrombosis after an
acute psychotic phase. They all died from
pulmonary embohsm without any comor-
bidity (Hindersin et al, 1984). Apart from
general papers deahng with mortahty m
psychiatnc hospitals (Licht et al, 1993;
Hewer et al, 1995), until recently this 1984
paper was the last pubhshed paper on the
specific subject of venous thrombosis in
psychiatnc patients. However, the subject
found new attention m a study of Walker
et al (1997) and Hagg et al (2000).
Case-control analysis
Baselme charactenstics of out-patients with
a first episode of venous thrombosis («=474)
who used antipsychotic drugs, antidepres-
sants or benzodiazepmes and a matched
control group (n=474) are reported in
Table 2. A hip Operation, heart valve dis-
ease, heart rhythm abnormahties and mtra-
venous heroin use until l year pnor to the
first episode of deep-vem thrombosis was
reported äs comorbidity. Medication use
concernmg five different medication cate-
gones among patients with a first episode
of deep-vem thrombosis («=474) and the
control group («=474) is shown m Table 3.
In this table the medication use is reported
with mcreasmg restnctiveness: first, all
use; second, use restncted to the year pre-
cedmg the venous thrombosis; third, use
hmited to monotherapy. Four patients used
antipsychotic drugs compared with none in
the control group. Their mean age was 42.8
years. One of these patients also used an
antidepressant and a benzodiazepme. The
antipsychotic drugs used were levomepro-
mazme, fluphenazme (both phenothiazines)
and halopendol. Antidepressant use differed
between subjects in the case and control
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Table 2 Baselme charactenstics of out-patients usmg antipsychotic drugs, antidepressants or benzodiazepmes in cases with a first episode of deep-vem thrombosis
(n=474) and a control group (n=474) dunng a penod mcluding the mdex year
Patients with deep-vem thrombosis Control



















































groups and yielded an odds ratio of 2.3 (95 %
CI 0.6-10.6). Medication use in general,
such äs beta-blockmg agents and antacids,
did not differ between patients and controls.
DISCUSSION
Autopsy series
A review of the Leiden Umversity Hospital
autopsy records in which pulmonary embo-
hsm was the sole cause of death led to the
unanticipated fmding of a large number of
psychiatnc patients with antipsychotic drug
use. The fmding that about one in three
patients with idiopathic fatal pulmonary
embohsm were referrcd from a psychiatnc
Institute was surpnsmg because on average
over the past 10 years the referral rate of
such patients m autopsies was only 5-
10% However, it cannot be excluded that
selective factors leadmg to autopsy might
have led to the large number of psychiatnc
patients in our series, äs we discussed m our
original report (Vandenbroucke et al,
1998). Because of this possible selection
blas the hypothesis of antipsychotic drugs
äs a possible nsk factor for deep-vem
thrombosis was 'data-driven'.
Historical literature overview
Predommantly German literature between
1953 and 1984 confirmed a high preva-
lence of thrombosis in psychiatnc patients,
also with an association with antipsychotic
use. Unfortunately, specific Information
about the diagnoses, medication use and
physical circumstances under which the
thrombosis occurred were often missmg.
Case-control analysis
Our fmdings in the re-analysis of the case-
control study are compatible with the
hypothesis of antipsychotic drugs äs a poss-
ible risk factor for deep-vem thrombosis.
Moreover, the original study excluded all
m-patients, also psychiatnc m-patients, so
that our conclusions relate only to out-
patient antipsychotic drug use. As the
numbers are small, confidence mtervals
are wide In consequence the results in
themselves are not conclusive.
Recent literature
Our results are m line with a 1992 pubhca-
tion reportmg an impressive 17-fold mcrease
in risk of myocardial mfarction observed
among young women usmg psychotropic
drugs and also an almost three-fold m-
creased risk of venous thrombo-embolism
(Thorogood et al, 1992). A similar recent
observation came from a study on mortahty
in clozapme users. Among current users of
clozapine, 19 cases in 85 399 person-years
of fatal pulmonary embohsms were found
This nsk was mcreased 5.2-fold when
compared with the non-use of clozapine
(Walker et al, 1997). Most recently,
Zornberg 8c Jick (2000) studied a baseline
population of 29 952 recipients of anti-
psychotic drugs. They found an odds ratio
of 3 3 for high-potency antipsychotic drugs
such äs halopendol and an odds ratio of
Table 3 Out-patients with a first episode of deep-vem thrombosis (n=474) and a control group (n=474) usmg psychotropic drugs, beta-blockers and antacid
monotherapeutics dunng a penod mcluding the mdex year, excludmg the mdex year and of monotherapy medication use only
Medication Includmg mdex year Excludmg mdex year Monotherapy use excludmg mdex year
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24.1 for low-potency antipsychotic drugs
such äs chlorpromazine.
Biological mechanism
The biological mechanism explaining the
relation between antipsychotic drugs and
venous thrombosis is unknown. Multiple
hypotheses have been postulated. In the most
recent publications of Zornberg & Jick
(2000) and Hagg et al (2000) three possible
mechanisms are discussed: antipsychotic
drugs enhance aggregation of platelets; anti-
cardiolipin antibodies are associated with
increased risk of thrombosis and their levels
are raised in some patients using chlorpro-
mazine; and venous stasis is exacerbated
by sedation. An alternative explanation
can be found in the article of Hindersin
et al (1984): the acute psychotic phase is
associated with an increase of adrenaline
secretion, which enhances the coagulation
mechanism.
Venous thrombosis appears to be asso-
ciated with the use of antipsychotic drugs
in psychiatric patients. Clinicians should
be aware of this possible relation when pa-
tients using antipsychotic drugs have com-
plaints such äs ehest pain or dyspnoea.
However, it cannot be completely excluded
that the findings on antipsychotic drugs are
an expression of some other underlying risk
factors of the disease itself. Also, the use of
these drugs might predispose to venous
thrombosis because of other medication
effects such äs sedation and immobilisation.
Because of the clinical implications we con-
clude that the association between venous
thrombosis and psychiatric illness is worthy
of renewed investigation, with an emphasis
on the mechanisms that might elucidate a
direct effect of antipsychotic drugs.
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